HTA logic as a strategic framework for market architecture and value realization in the life sciences sector

HTA as a Logic of Assessment and Structuring Principle

HTA systems assess the added benefit of an intervention compared with the current standard of care under real-world care conditions. Institutions such as IQWiG or NICE follow clearly defined methodological frameworks.

At the center is the assessment of patient-relevant endpoints compared with an established therapy. Scientific plausibility alone is not enough. What matters is whether a clinically meaningful difference can be demonstrated under realistic conditions.

This logic makes clear that HTA is not an isolated process. It is the organizing principle around which development, evidence, and pricing must align.

HTA-driven Value Architecture as a Methodological Framework

To make this logic systematically usable, HTA can be operationalized as an integrated framework across the entire value chain.

The following framework outlines the core decision logic:

HTA-driven Value Architecture

HTA connects three levels:

• Value definition

• Evidence generation

• Value realization

These levels are specified through five sequential building blocks.

1. Target population and care context

Guiding question: In which real-world care setting is the product being assessed?

Assessment does not begin with the overall population, but with the actually addressable patient group. Diagnosis rates, access to care, and the reality of care structure this population. A typical mistake is to work with theoretical patient numbers without any connection to care delivery.

The target population defines the framework within which an assessment can be made at all.

2. Comparator anchor and standard of care

Guiding question: Against which therapy is the benefit measured?

HTA is aligned with the real-world standard of care, not with the regulatory trial design. Differences between markets play a central role here. A typical mistake is to equate the regulatory comparator with the HTA-relevant comparator.

The comparator anchor sets the benchmark for added benefit and price.

3. Evidence and endpoint logic

Guiding question: Which evidence is recognized as decision-relevant?

Patient-centered endpoints, external validity, and proximity to care are the focus. Surrogate markers are accepted only to a limited extent. Focusing on statistical significance without HTA relevance is a typical mistake here.

4. Added benefit and differentiation

Guiding question: Is the difference clinically and economically meaningful?

Added benefit is assessed against the existing therapy. Subgroups and lines of therapy play an important role. Differentiation that is insufficiently substantiated must therefore be avoided.

Without robust added benefit, no sustainable value is created.

5. Price and reimbursement logic

Guiding question: How is value translated into economic reality?

Pricing follows the assessment of added benefit. The comparator therapy defines the reference framework for price negotiations. A typical mistake is to consider price and evidence separately.

Price is the result of the HTA assessment, not its starting point.

Implications for development programs

The framework makes clear that HTA must already be taken into account in early development phases. The choice of comparator, the definition of endpoints, and the selection of the study population determine whether added benefit can be demonstrated later at all.

Programs that ignore this logic create structural evidence gaps that cannot be closed in later stages.

HTA is a design criterion for development, not a checkpoint at the end.

Integration of HTA and pricing strategy

Pricing is directly linked to the HTA assessment. In many European markets, demonstrated added benefit determines the room for negotiation. The framework shows that price cannot be developed in isolation. It is the result of the overall evidence strategy. A lack of added benefit leads to pricing based on existing therapies and thus to limited economic attractiveness.

Pricing strategy is the economic translation of HTA logic.

Relevance for investors and company valuations

For investors, HTA is a key factor in assessing programs. Regulatory approval alone is not a sufficient indicator of economic success. What matters is whether robust added benefit can be generated and translated into a viable pricing strategy. The framework enables a structured assessment of this question and highlights risks at an early stage.

HTA determines whether scientific progress can be converted into investable value.

HTA as the organizing principle of market architecture

HTA connects clinical development, regulatory requirements, and commercial strategy into an integrated market architecture. Organizations that achieve this integration make consistently better decisions and reduce risks along the entire value chain. The framework serves as the unifying decision logic.

HTA is the central organizing principle for market architecture and value realization.

Conclusion

HTA defines how value is measured and recognized in the healthcare system. It is not a downstream process, but a strategic framework that influences key decisions throughout development. Integrating HTA logic through the framework presented here enables a consistent link between development strategy, evidence generation, and pricing.

Organizations that pursue this approach increase the likelihood of translating scientific progress into economic success.

About Excellere LifeScience Consulting

In practice, HTA is often addressed too late. The consequences are avoidable evidence gaps, limited price negotiations, and delayed market access. The framework presented here provides a structured basis for systematically integrating HTA into market architecture and linking it early on with development and pricing strategies.

Excellere LifeScience Consulting supports life sciences companies and investors in translating this logic into concrete decision-making processes.